[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641569":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":58,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":102,"studyType":103,"phases":10,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"GROUP_1_Lowland (\u003C500 m)",null,"Participants residing at altitudes below 500 meters. Enrollment sites include Shanghai (4 m), Guangzhou, Suzhou, Hangzhou, Wuhan, Changsha, Nanjing, and Zhengzhou.",[13],"Other: No Intervention: Observational Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"GROUP_2_Intermediate (500-2,000 m)","Participants residing at altitudes between 500 and 2,000 meters. Enrollment sites include Kunming (1,890 m), Guiyang (1,100 m), Lanzhou (1,520 m), Yinchuan (1,100 m), Xi'an (400 m - borderline, verify), Chengdu (500 m), and Chongqing (240 m).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"GROUP_3_Highland (2,000-3,500 m)","Participants residing at altitudes between 2,000 and 3,500 meters. Enrollment sites include Xining (2,295 m), Golog (3,700 m - verify), Haixi (2,980 m), Yushu (3,700 m), and Ganzi (3,400 m).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"GROUP_4_Extreme Altitude (>3,500 m)","Participants residing at altitudes above 3,500 meters. Enrollment sites include Lhasa (3,656 m), Nagqu (4,500 m), and Ali (4,500 m).",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"No Intervention: Observational Cohort","No intervention; observation of altitude exposure and SpO₂ levels",[9,15,19,23],[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Zhigang Lan, M.D. PhD.","CONTACT","18980606446","158075478@qq.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","China","CN",{"type":46,"coordinates":47},"Point",[48,49],104.06667,30.66667,{"lat":49,"lon":48},[52,53],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},{"name":10,"role":34,"phone":10,"phoneExt":10,"email":36},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhigang Lan","Professor",[59,61,63,65,67,69,71,73,75,77,79,81,83,85],{"name":60,"class":6},"Affiliated Hospital of Qinghai University",{"name":62,"class":6},"Tibet Autonomous Region People's Hospital",{"name":64,"class":6},"Kunming Medical University",{"name":66,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":68,"class":6},"First Affiliated Hospital of Suzhou Medical College",{"name":70,"class":6},"First People's Hospital of Hangzhou",{"name":72,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"name":74,"class":6},"Guiyang No.1 People's Hospital",{"name":76,"class":6},"Lanzhou University Second Hospital",{"name":78,"class":6},"The First People's Hospital of Yinchuan",{"name":80,"class":6},"Second Affiliated Hospital of Xi'an Jiaotong University",{"name":82,"class":6},"First Affiliated Hospital of Chongqing Medical University",{"name":84,"class":6},"The First People's Hospital of Xining City",{"name":86,"class":6},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","100641569","high-altitude-neurodegeneration-cohort-hanc-study-100641569",false,"NCT07657520","High-Altitude Neurodegeneration Cohort (HANC) Study","High-Altitude Neurodegeneration Cohort (HANC) Phase II: A Prospective Multicenter Validation Study on the Association Between Chronic Physiological Hypoxia and Multiple System Atrophy","HANC","Inclusion Criteria:\n\n1. Self-identified Han Chinese ethnicity\n2. Age between 40 and 75 years (inclusive)\n3. No prior diagnosis of parkinsonism at baseline\n4. Permanent residence at study site location for ≥1 year prior to enrollment\n5. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Pre-existing diagnosis of Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or any other parkinsonian disorder at baseline\n2. Severe chronic pulmonary disease (e.g., COPD GOLD stage ≥3) affecting baseline SpO₂ measurement\n3. Severe cardiovascular disease (e.g., New York Heart Association Class III or IV heart failure)\n4. Cognitive impairment precluding completion of study procedures\n5. Current enrollment in any interventional clinical trial\n6. Life expectancy \\\u003C12 months due to any medical condition",true,"ALL","40 Years","75 Years",{"count":100,"type":101},20000,"ESTIMATED","12 Months","OBSERVATIONAL","Chronic physiological hypoxia has been implicated in the pathogenesis of multiple system atrophy (MSA), a fatal neurodegenerative disorder of unknown etiology. This prospective, multicenter, observational cohort study (Phase II of the High-Altitude Neurodegeneration Cohort \\[HANC\\] study) aims to validate the association between chronic hypoxia exposure and incident MSA risk. A total of 20,000 Han Chinese participants aged 40-75 years will be enrolled from 23 sites across China spanning an altitude gradient from 4 m to 4,500 m. All participants will undergo standardized in-person assessment including questionnaires, physical examination, blood collection, and 3-night consecutive nocturnal pulse oximetry monitoring. Participants are to be followed for incident MSA over 12 months. The primary outcome is newly diagnosed MSA (probable or definite per Gilman consensus criteria), adjudicated by an independent panel of movement disorders specialists. Secondary outcomes include the association between altitude strata and MSA incidence, the association between mean nocturnal SpO₂ and MSA incidence, and incidence rates across MSA subtypes (MSA-P and MSA-C).",[106],"Multiple System Atrophy",[108,109],"Chronic Hypoxia","Altitude Sickness","2026-07-07",{"date":112,"type":113},"2026-07-09","ACTUAL",{"date":115,"type":113},"2026-06-13",{"date":117,"type":101},"2027-07-30",{"name":5,"class":6},1]